Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35704787/
Venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA is an effective regimen among older or unfit patients with newly diagnosed AML. The rates of overall survival and DFS are encouraging....
Conclusion: Venetoclax and CLAD/LDAC alternating with venetoclax and 5-AZA is an effective regimen among older or unfit patients with newly diagnosed AML. The rates of overall survival and DFS are encouraging. Further study of this non-anthracycline-containing backbone in younger patients, unfit for intensive chemotherapy, as well as...
A Case of Concurrent Leukocytosis and Systemic Capillary Leak Syndrome Due to Pegfilgrastim
Pegfilgrastim is a granulocyte colony-stimulating factor agent used in patients receiving myelosuppressive therapy with chemotherapy or radiation. Two adverse effects associated with this agent include capillary leak syndrome and leukocytosis....
Conclusion/Relevance: Pegfilgrastim is a granulocyte colony-stimulating factor agent used in patients receiving myelosuppressive therapy with chemotherapy or radiation. Two adverse effects associated with this agent include capillary leak syndrome and leukocytosis. To our knowledge, this is the first case of a patient who developed both systemic...
Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35667958/
The majority of recombinant mAb products contain heterogeneous charge variants, commonly the result of post-translational modifications occurring during cell culture and accumulated during production, formulation and storage. MB02 is a...
Conclusion/Relevance: The majority of recombinant mAb products contain heterogeneous charge variants, commonly the result of post-translational modifications occurring during cell culture and accumulated during production, formulation and storage. MB02 is a biosimilar mAb to bevacizumab. Similarity data of charge variants for biosimilars...
Wellcome Open Research Article: A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report.
Source : https://wellcomeopenresearch.org/articles/6-360/v1
Read the latest article version by Anna Rowan, Chris Bates, William Hulme, David Evans, Simon Davy, Nicholas A Kennedy, James Galloway, Kathryn E Mansfield, Katie Bechman, Julian Matthewman, Mark Yates,...
Background: At the outset of the COVID-19 pandemic, there was no routine comprehensive hospital medicines data from the UK available to researchers. These records can be important for many analyses including the effect of certain medicines on the risk of severe COVID-19 outcomes. With the approval of NHS England, we set out to obtain data on...
Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
Source : https://www.wjgnet.com/2307-8960/full/v10/i14/4327.htm
The idiopathic Inflammatory Bowel Disease (IBD) phenotypically presents as ulcerative colitis (UC) and as Crohn's disease (CD). Unlike UC, which exclusively affects the colon's mucosal layer, CD damages all layers...
Core Tip: There is limited evidence on the safety and use of biosimilars other than Infliximab. This review explores the role of biosimilars in an era of anti-tumor necrosis factor-α drug as a treatment option for inflammatory bowel disease. The approval of biosimilars by the Food and Drug Administration or European Medicines Agency based on...